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Abstract 
Aim 
Ketamine can induce hepatotoxicity which has been suggested to be dependent on mitochondrial 
impairment. This study investigated the long-term effects of chronic low-dose ketamine on liver 
mitochondrial function, oxidative stress parameters, liver histology and glycogen content. 
Main methods 
Adult rats were administered with saline or ketamine (5 or 10 mg/kg) twice a day for a fourteen-day period 
in order to mimic chronic treatments. Effects between groups were compared ten days after the treatment 
had ended. Liver mitochondrial function was monitored in isolated mitochondrial extracts through 
evaluation of respiration parameters and activity of respiratory complexes, as well as oxidative stress, 
through lipid peroxidation, protein oxidation and superoxide dismutase activity. The hepatic histology and 
liver glycogen content were also evaluated. 
Key findings 
Ketamine groups showed a decreased evolution in body weight gains during the treatment period. Ketamine 
had no effect either on serum liver enzymes or on the oxidative stress parameters of liver mitochondria. 
Ketamine decreased the hepatic glycogen content, inhibited mitochondrial complex I and oxygen 
consumption when glutamate–malate substrate was used. 
Significance 
These findings reflect a long-term mitochondrial bioenergetic deterioration induced by ketamine, which 
may explain the increased susceptibility of some patients to its prolonged or repeated use. 
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Introduction 
Ketamine has gained a renewed interest for depression and chronic pain management, since it has an 
immediate and persistent effect on a high percentage of cases in which the classic therapeutic is not effective 
(Correll et al., 2004 and Zarate et al., 2006). Moreover, ketamine is being increasingly used as a recreational 
drug (Morgan et al., 2010). However, hepatotoxic side effects have been frequently described after repeated 
exposure to it (Correll et al., 2004 and Noppers et al., 2011). Ketamine's exact biochemical mechanism for 
hepatotoxicity is not fully understood, although mitochondrial dysfunction implications have been 
suggested as a possible explanation (Noppers et al., 2011). The liver is a very active metabolic organ with 
a high number of mitochondria and very susceptible to drugs acting on mitochondria, which may interfere 
with bioenergetic function and redox homeostasis (Boelsterli and Lim, 2007 and Szewczyk and Wojtczak, 
2002). 
Ketamine is metabolised in the liver by the cytochrome P-450 microsomal system (Chan et al., 2005). In 
human patients, hepatic injuries have been reported after ketamine anaesthetic infusions (Blunnie et al., 
1981 and Kiefer et al., 2008) and in the course of long chronic pain treatments (Correll et al., 
2004 and Noppers et al., 2011). In vitro studies suggest that mitochondrial dysfunction has an important 
role on ketamine liver induced injuries (Chang et al., 2009, Lee et al., 2009 and Markham et al., 1981). 
When exposed to ketamine, hepatocytes showed an inhibition of oxidative phosphorylation (Chang et al., 
2009), increased apoptotic insults (Lee et al., 2009) and reactive oxygen species (ROS) production (Reinke 
et al., 1998). Contrarily, ketamine also showed hepatoprotective effects which are attributed to its anti-
inflammatory properties (Suliburk et al., 2005). 
Despite several in vitro studies (Chang et al., 2009, Lee et al., 2009 and Markham et al., 1981), there is still 
little information on ketamine chronic effects on liver mitochondria and oxidative stress responses when in 
vivo models are used. Very recently, Kalkan et al. (2013) have referred hepatic pathologic changes with 
mitochondrial degeneration in rats which had been administered high doses of ketamine for two weeks 
(Kalkan et al., 2013). In addition, we had previously reported that rats subject to a similar period of chronic 
low doses of ketamine showed persistent behavioural alterations and loss of weight gain (Venancio et al., 
2011). Thus, this study was designed to look into the long-term effects on the liver mitochondrial 
bioenergetic function, oxidative stress parameters and liver glycogen content following a chronic low dose 
ketamine treatment in adult rats. 
Material and methods 
Animals and drug treatment 
All procedures used were approved by the local ethical committee and by the Portuguese Agency for 
Animal Welfare, General Board of Veterinary Medicine, in compliance with the European Community 
Council Directive of September 22, 2010 (2010/63/UE). All efforts were made to ensure minimal animal 
stress and discomfort. 
Twenty-one adult male Wistar rats (90–110 days) acquired from Charles River (Barcelona, Spain) were 
randomised in three groups. Animals were kept under controlled environmental conditions of temperature 
(20 ± 1 °C), relative air humidity (45–55%), maintained in a 12-h light/dark cycle and housed in groups of 
two or three per cage with standard rodent food and water supplied ad libitum. 
Ketamine (Imalgene1000® Merial, Portugal, 100 mg/ml) was freshly diluted before subcutaneous injection 
in a volume of 1 ml/kg of body weight. Groups were administered with saline solution (K0), 5 mg/kg 
ketamine (K5) or 10 mg/kg ketamine (K10). Doses were established in accordance with previous studies 
for analgesic (Wang et al., 2000) or antidepressant properties in rats (Li et al., 2010). Injections were given 
twice daily (9:00/21:00 h) for 14 consecutive days to achieve a chronic effect (Garcia et al., 2008). The 
body weight gains were monitored daily throughout the experimental period. Rats were killed 10 days after 
the last administration (24th day of experiment) by decapitation and blood samples were obtained. The liver 
was rapidly removed for mitochondrial isolation, histology analysis and glycogen determination. 
Reagents 
Substrates, enzymes and standard chemical reagents were of the highest grade commercially available and 
obtained from Sigma (Sigma-Aldrich, Steinheim, Germany). All solutions were prepared with ultra-pure 
water purified by a Milli-Q Gradient system (Millipore, Bedford, USA). 
Liver enzyme activity measurements 
The measurement of the hepatocellular enzymes alanine aminotransferase, aspartate aminotransferase and 
gamma-glutamyl transferase in the blood stream was used as an index of hepatic injury. Blood samples 
were stored at 4 °C for 1 h; after clotting, they were centrifuged for 10 min at 2800 g. Serum levels of 
enzyme activity were measured at 37 °C by standard clinical chemical methods using an automatic analyzer 
type Architect ci8200 (Abbott Laboratories Ltd., USA). 
Liver histology 
Liver samples were processed by standard techniques and submitted to histologic examination (light 
microscopy). Briefly, samples were immersed in 10% buffered formalin and embedded in paraffin wax 
prior to sectioning. For each sample, three series of three sections (3 μm thick) were cut and stained with 
haematoxylin and eosin or periodic acid-Schiff (PAS) reagent method to detect glycogen as previous 
described (Bancroft and Stevens, 2002). Diastase for glycogen digestion was used as control. Morphologic 
analysis was made by a pathologist who was blinded to the experimental protocol. The hepatic morphologic 
characteristics and increase of areas with glycogen (PAS +) sensitive to digestion with diastase were 
assessed. The selection of hepatic areas for glycogen content evaluation in hepatocytes was done according 
to previously described methods (Stadler et al., 2005). Digital photomicrographs of each section were taken 
(Nikon 4500 Coolpix, USA). Each sample section was graded as follows for PAS + areas: mild (+) — all 
areas showing slight PAS +; moderate (++) — a combination of areas with slight PAS + and others with 
intense PAS + staining; high (+++) — extensive and marked areas with intense PAS + staining. 
Glycogen analysis 
Liver homogenate was used for glycogen concentration determination using phenol–sulphuric method as 
described previously (Bennett et al., 2007). This was read at 490 nm, 30 min after incubation (Cary 100 
Bio, Varian Analytical Instruments, USA). 
Isolation of liver mitochondria 
The isolation was performed as described previously (Peixoto et al., 2002). The homogenization medium 
contained 225 mM mannitol, 75 mM sucrose, 10 mM Hepes (pH 7.4), 2 mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) and 0.1% fatty acid-free bovine serum albumin 
(BSA). EGTA and BSA were omitted from the final washing medium. The final concentration of 
mitochondrial protein was determined by the Biuret method, using BSA as standard. 
Liver mitochondrial respiratory activity 
Oxygen consumption of isolated mitochondria was monitored polarographically with a Clark-type oxygen 
electrode, using a Hansatech Oxygraph measurement system (Hansatech, Norfolk, UK) at 25 °C. 
Mitochondria (0.5 mg) were incubated, for 2 min in 1 ml of reaction medium (100 mM sucrose, 100 mM 
KCl, 2 mM KH2PO4, 5 mM Hepes, 10 μM EGTA, pH 7.4). The mitochondria were energised with 
glutamate–malate (complex I substrate) or succinate (complex II substrate). Oxygen consumption was 
measured in the absence (state 4) or presence of 100 μM ADP (state 3). Respiratory rates were expressed 
in nmol O2/citrate synthase activity. Respiratory control ratio (RCR = state 3/state 4) was calculated (Vilela 
et al., 2009). 
Liver mitochondrial enzymatic activity assays 
Before the enzyme assays, the mitochondrial frozen samples (at − 70 °C) were freeze-thawed three times 
to disrupt their membranes. All the enzymatic assays were performed on a temperature controlled chamber 
with stirring and were performed in triplicate in a microplate apparatus (Power Wave XS2, Biotek, USA). 
Citrate synthase activity was determined as described previously at 30 °C (Shepherd and Garland, 1969) 
with slight modifications. The reaction mixture contained 100 mM Tris–HCl buffer (pH 8.0), 5 mM MgCl2, 
0.5 mM 5,5-dithio-bis-2-nitrobenzoic acid, 0.2 mM acetyl CoA, 1 mM oxaloacetic acid and broken 
mitochondria (15–25 μg). The decrease of acetyl CoA absorption was monitored at 412 nm and specific 
activity, as units of citrate synthase activity/min ∙ mg of protein, was calculated and used to normalise the 
other mitochondrial functional parameters. 
The electron transport chain complexes I, II, III and IV were quantified by spectrophotometric assay as 
previously described (Kiebish et al., 2008). Complex V (ATPase) activity was determined by monitoring 
the pH change associated with ATP hydrolysis (Peixoto et al., 2002). 
Liver mitochondrial oxidative stress parameters 
Lipid peroxidation was determined measuring malondialdehyde equivalents, using the thiobarbituric acid 
assay, as previously described (Alves et al., 2007). Protein carbonyls were quantified through the 
spectrophotometric carbonyl assay, as recently described (Hawkins et al., 2009), using 2, 4-
dinitrophenylhydrazine. Superoxide dismutase activity was determined as described previously (Paya et 
al., 1992). 
Statistical analysis 
Comparisons were made by one-way ANOVA followed, when appropriated, by Tukey's post hoc test. 
Repeated-measures ANOVA was used for weight gain analysis. Results are expressed as mean ± SEM. The 
statistical level of significant was considered at p < 0.05, using the GraphPad Prism 6.0 (GraphPad 
Software, San Diego, CA, USA). 
Results 
Body weight gain 
The chronic ketamine administrations induced a decrease in body weight gain during the experimental 
period F(2,17) = 32.44, p < 0.0001, (Fig. 1). No mortality was observed between groups; however, one rat 
was excluded for displaying aggressive behaviour. The results revealed decreased body weight gain among 
the K0 and the ketamine groups after the second day of treatment (p < 0.05). The weight recovery started 
on day ten for both ketamine groups. The K5 group showed less accentuated differences and after the 
twenty-second day no significant differences were observed by comparison with K0 group (p = 0.79). Both 
groups failed to reach the control values. Moreover, except for day two, the K10 group showed a significant 
reduction in body weight gain compared to the K5 group (p < 0.05). 
 
 
 
Blood evaluation 
The activities of biochemical markers of liver damage, such as alanine aminotransferase and aspartate 
aminotransferase, were not significantly different between groups. The levels of gamma-glutamyl 
transferase were below the detection limits (< 4 IU/l) in all samples. 
Liver histology and glycogen concentration 
In all samples, the liver showed normal histological features with no increase in the number of degenerating 
cells, fibrosis or infiltrated inflammatory cells. However, with recourse to the PAS method (Fig. 2) and by 
the spectrophotometrical assay using phenol–sulphuric method, we were able to observe that the livers from 
rats exposed to ketamine displayed lower levels of glycogen concentration than in those of rats from the 
control group, F(2,17) = 5.531, p = 0.014, (Fig. 3). Detailed analysis revealed that K10 treatments decreased 
glycogen content in hepatocytes (p < 0.05). 
 
 
Liver mitochondrial functionality 
Oxygen consumption with substrates for complex I (glutamate–malate) and II (succinate) was observed. 
The main effect of treatment in mitochondrial respiration initiated by glutamate–malate was seen in state 
3, F(2,15) = 6.704, p = 0.0083, (Fig. 4A) and state 4, F(2,15) = 34.84, p < 0.0001, (Fig. 4B). Detailed 
analysis revealed that, when the respiratory chain was activated by glutamate–malate, both K5 and K10 
treatments decreased oxygen consumption in state 3 (p < 0.05) and state 4 (p < 0.0001). But when succinate 
was used as substrate, no significant differences were observed in these parameters (Fig. 4D and E). 
 The respiratory control ratio is a measure of the dependence on the respiratory rate with oxidative 
phosphorylation. This study showed no significant difference between experimental groups in RCR for 
both respiratory substrates (Fig. 4C and F). 
The activity of complex I was significantly inhibited by ketamine doses F(2,17) = 14.06, p = 0.0002, 
(Fig. 5A). Complex I was reduced by 41.1% and 45.6% for K5 (p < 0.01) and K10 (p < 0.001), respectively, 
in comparison with control group. The specific enzymatic activities of complexes II, III and IV were not 
significantly affected by ketamine treatments (Fig. 5B, C and D). The activity of complex V showed a trend 
to decrease F(2,17) = 3.133, p = 0.0695, (Fig. 5E), with a reduction of 45.0% and 28.3% in groups K5 and 
K10, respectively, in comparison with the control group. 
  
Liver mitochondrial oxidative stress 
The lipid peroxidation, protein carbonyls and superoxide dismutase activity evaluated in liver mitochondria 
were not significantly different between groups (data not shown). 
Discussion 
This work shows that chronic ketamine treatment with a lower dose in rats impairs liver mitochondrial 
complex I and decreases liver glycogen content as well as body weight gain. Nevertheless, neither other 
hepatic histological changes nor significant hepatotoxicity effects were observed. 
The body weight gain is a parameter usually used as a health indicator in chronic rodent toxicology studies 
(Rhomberg et al., 2007). Chronic low ketamine doses have induced a significant loss of body weight gain. 
These results are consistent with other previous observations (Venancio et al., 2011). At the end of the 
experimental period, only the higher ketamine group showed a significant weight reduction. A possible 
explanation for the decrease of body weight gain could be related to the fact that ketamine induces nausea 
and vomiting with consequent loss of appetite as observed in humans (Cvrcek, 2008). Moreover, nausea 
and vomiting are associated with liver injury (Verma and Kaplowitz, 2009). However, we did not observe 
alterations in enzymatic biomarkers for liver injury. Similarly, in humans, after chronic pain management 
with ketamine, no significant alterations of liver enzymes were shown (Amr, 2010, Cvrcek, 
2008 and Sigtermans et al., 2009). This could also be the result of biochemical analysis having been 
performed ten days after the last ketamine administration; also, as it happened with humans, an increase of 
liver enzymes was observed but it went back to normal values between ten days and two months after the 
pain treatment had ended (Kiefer et al., 2008 and Noppers et al., 2011). Another likely explanation for the 
decrease of body weight gain may be related to the fact that, being an N-methyl-D-aspartate (NMDA) 
receptor antagonist, ketamine may have brain interference in food intake (Popik et al., 2011 and Wu et al., 
2012) and also hepatic metabolism regulation implications (Lam et al., 2010). 
This study showed a decrease of hepatic glycogen concentration in the higher ketamine group, which was 
also corroborated by histological observations. Otherwise, no hepatic histological changes were observed. 
Reduced glycogen store in hepatocytes is related to an increased susceptibility to hepatotoxicity (Stadler et 
al., 2005). In mice, chronic ketamine treatment also decreases glycogen in liver, reflecting either a failure 
of glycogen synthesis or an increase of glycogenolysis (Wong et al., 2012). Other studies also reported that 
ketamine can promote hepatic bioenergetic deterioration with concomitant reduction of ATP production 
(Takahashi et al., 1998), gluconeogenesis (Sear and McGivan, 1979) and increased glycogenolysis 
(Machado et al., 2009) which may be associated with an increase of blood glucose levels (Dawson et al., 
2013 and Rodrigues et al., 2006). 
Hepatic bioenergetic deterioration reflected by the decrease in glycogen is usually coupled with reduction 
of ATP production (Gallis et al., 2011). Ketamine decreased the oxygen consumption in state 3 and state 4 
when complex I was energised. This may result from the observed inhibition of complex I (NADH 
ubiquinone oxidoreductase) activity. Similar effects of ketamine in hepatic cell cultures have been recently 
observed such as time-dependent interruption of microtubular cytoskeleton remodelling, decreased 
intracellular levels of calcium concentrations and concurrent reduction of ATP production due to down-
regulation of the mitochondrial membrane potential and complex I activity (Chang et al., 2009). When 
succinate was used as substrate, there were neither significant alterations, nor significant change in the 
activity of other electron transport chain complexes which confirms that the previous reported decrease in 
oxygen consumption is due to a direct effect on complex I. In line with these findings, it has been reported 
that ketamine induces mitochondrial complex I impairment on isolated rat liver mitochondria (Markham et 
al., 1981). However, a normal value of RCR in ketamine groups for the two substrates used also indicates 
that the structural integrity of mitochondria was not affected. Complex I is the first enzyme of the 
respiratory chain and plays a central role in oxidative phosphorylation (Efremov et al., 2010). Its inhibition 
promoted by ketamine and by other anaesthetics may be related to the interference in glucose metabolism 
(Biebuyck et al., 1972). 
Complex I inhibition can exacerbate mitochondrial ROS generation. Nevertheless, due to its antioxidant 
capacity, mitochondria can rapidly degrade ROS (Brown and Borutaite, 2012). This can account for the 
absence of lipid peroxidation and protein oxidation in liver mitochondria obtained from rats treated with 
ketamine. Moreover, the literature concerning ROS production as a result of ketamine anaesthesia is 
controversial; in fact, several studies show that it decreases (Saricaoglu et al., 2005), or has no effect at all 
(Alva et al., 2006), while others claim it does, indeed, increase ROS production (Reinke et al., 1998). 
Furthermore, pre-treatment with ketamine can potentiate hepatotoxicity of other compounds by increasing 
oxidative stress (Rofael, 2004). 
As far as we know, this is the first in vivo low-dose ketamine study to evaluate liver effects, liver 
mitochondrial function and oxidative stress. A recently published study showed that a two-week high-dose 
ketamine administration in rat models induced hepatic pathologic changes with mitochondrial degeneration 
associated with a decreased hepatic expression of calcineurin, a protein phosphatase regulated by calcium 
(Kalkan et al., 2013). Based on works from Wang et al. (2000) and Garcia et al. (2008), the doses used are 
within the therapeutic use. The results thus obtained confirmed the critical role of ketamine on 
mitochondrial complex I impairment and bioenergetic deterioration (Chang et al., 2009 and Markham et 
al., 1981). Ketamine hepatotoxicity's mechanism is still unclear, but this work has the relevance of showing 
impairment effects in mitochondrial complex I ten days after the end of chronic ketamine treatment. This 
effect may be the result of a direct ketamine action in complex I or of a likely decrease in calcium levels, 
but it also indicates insufficient mitochondrial recovery systems after chronic ketamine treatment. It has 
been reported that change in the mitochondrial function increases sensitivity to anaesthetics (Morgan et al., 
2002). Therefore, on the clinical level, complex I impairment and the decrease in hepatic glycogen content 
could justify the susceptibility of some patients to prolonged or repeated use of ketamine in humans for 
chronic pain management (Correll et al., 2004 and Noppers et al., 2011). 
Conclusion 
In summary, our findings failed to show chronic low dose ketamine effects on ROS production and in 
enzymatic biomarkers for liver injury. Results showed a decrease of mitochondrial complex I activity and 
glycogen levels. These liver effects point to the need of precaution in ketamine administration and may 
explain the increased susceptibility of some patients to its prolonged or repeated use. 
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